RocheSuper Heavyweight Oncology"Three Horses Driving the Cart"The revenue performance has always been highly regarded in the industry. Its three flagship drugsRitual(MabThera, generic name: Rituximab Injection)、Herceptin(Herceptin, Generic Name: Trastuzumab for Injection)And Avastin (Avastin, Generic Name: Bevacizumab InjectionKnown as Roche's "Three Horses".These drugs are all targeted for tumor treatment, with unique mechanisms of action and good efficacy, consistently.PreparationAffectedIndustry Attention. Currently,BevacizumabThe market competition has entered a white-hot stage, and pharmaceutical companies in China are actively making their mark, hoping to stand out in the fierce competition.

BevacizumabOriginal Research byRocheDevelopment, is an anti-vascular endothelial growth factor monoclonal antibody that can specifically bind toBinding to VEGF, blocking the binding of VEGF to its receptors, thereby reducing the formation of new blood vessels, inducing the regression of existing blood vessels, and inhibiting tumor growth. It was launched in the United States in 2004 and in China in 2010. The approved indications cover hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer, cervical cancer, and ovarian cancer, etc. As a broad-spectrum anti-tumor drug,BevacizumabHas become the globally recommended standard regimen in treatment guidelines for various malignant tumors.

In recent years, due to the impact of patent expiration, generic drug competition, and other factors,The entry of numerous companies' biosimilars has gradually eroded Roche's market share., OldThe revenue of the "three horses" has been on a downward trend.According to the data statistics from PharmaCloud,2021MabTheraSales in hospitals across China reached a high of1.9 billion yuan, but in 2022 it dropped to 1.3 billion yuan.At the same time,HerceptinAndAvastinSales also experienced a similar decline.In 2021,HerceptinSales in hospitals nationwide reached 4.6 billion yuan, and in 2022,Sales RevenueSlide down toRMB 4.1 billion.AvastinSalesIn2021Nationwide Hospital SalesAchieveRMB 2.1 billion, but plummeted to RMB 1.4 billion in 2022, indicating an unfavorable situation.

Source of screenshot: Pharma Intelligence China Pharmaceutical Sales Database

BevacizumabInTop 10 Companies in China's Hospital Sales in 2022Qilu PharmaceuticalSurpassed the original research with a 54% market shareRoche, marking the official end of the "exclusive period" for the original research market. At the same time,Innovent Bio, SUZHOU SUNCADIA BIOPHARMACEUTICALS CO.,LTDAndShandong BoAn Biotechnology Co. Ltd.Chinese pharmaceutical companies have also successfully made it to the market shortlist. Nowadays,BevacizumabAs market competition intensifies, former leaders are gradually fading while new powerhouses are emerging, injecting fresh vitality into the market landscape. This dramatic competition is undoubtedly set to bring more excitement and unpredictability to the pharmaceuticals industry.

Source of screenshot:Pharma Intelligence China Pharmaceutical Sales Database - Comprehensive Analysis

BevacizumabPatent protection in China expired in 2018, and in August 2018Qilu PharmaceuticalOfBevacizumabThe marketing application of a similar drug was accepted by NMPA and approved in December 2019 for the treatment of patients with advanced, metastatic, or recurrent non-small cell lung cancer and metastatic colorectal cancer. This also meansQilu PharmaceuticalNot only won the first domestically producedBevacizumabBiosimilars have also taken the lead in occupying the first-mover market advantage, sharing a large market share of nearly 3 billion yuan with Roche.(In 2019, the market sales of Bevacizumab in Chinese hospitals reached 3 billion yuan)。

Source of screenshot:PharmCube China Pharmaceutical Sales Database

With the rise in market sales, an increasing number of companies in China are coming to claim a share of this pie, in 2020.Innovent BioTheDa You Tong(Bevacizumab Injection)Following closely, it was approved for marketing in June, forming a "three kingdoms contention" situation. However, this market pattern was quickly broken.

In 2021, domestically producedBevacizumabSimilar drugs have entered a period of explosive growth, with a total of 6 products approved for marketing, includingShandong BoAn Biotechnology Co. Ltd., SUZHOU SUNCADIA BIOPHARMACEUTICALS CO.,LTD(Hengrui Medicine's wholly-owned subsidiary)、Bio-Thera, Betta Pharmaceuticals, Tot BiopharmAndShanghai Henlius Biotech, Inc.The market pattern has suddenly shifted from a "three-way battle" to a "competition among many kings."

Now,BevacizumabThe market competition has entered the second half.CHIATAI TIANQINGTheAmesAndSinocelltechTheAnbeizhuApproved for marketing in February and June 2023, respectively, indicating that the number of China-produced bevacizumab biosimilars has expanded to 10.Broke the monopoly of original drugs in the market, forming a 10+1 market pattern.

Source of Screenshot:PharmCube Database Integration

According to the data statistics from PharmaCloud, currently

In China, there is

Beijing Oriental Biotay Biotechnology, Jiangsu Aosaikang Pharmaceutical, Shanghai Kangdai BiomedicalMore than 20 companies including

Bevacizumab

The drug is in the clinical trial stage.

, pushing the field into a frenzied phase of "internal competition."

Screenshot source:PharmCube Global Drug Development

Recent Popular Resource Acquisition

Reply to the keyword " in the backgroundReport", access dozens of exclusive reports produced by PharmaCloud

Reply to the keyword " in the backgroundCSCO", Obtain 2023 CSCO Guidelines

Reply to the keyword " in the backgroundASCO", Obtain 2023 ASCO Abstracts by Cancer Type

Reply to the keyword " in the backgroundFirst Generic in 2022", Obtain the list of first generic drugs approved in 2022

Reply to the keyword "Medical Insurance", Obtain the 2022 Medical Insurance Catalog

   

Contact us to experience more professional services from PharmaCloud.
WillDiscussion CombinedWork	GardenDistrict FUMission	Database Consultation	Customization Service	Media Cooperation

ClickReadRead the Original Text, apply for a free trial of PharmaCloud Enterprise Edition!